

Table 9.26
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a
SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis
All Races, Males, 2010-2016

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
Lymphoid Neoplasm	105,719	71.7 (71.3 , 72.1)	90.5 (89.6 , 91.3)	77.6 (77.2 , 78.1)	62.7 (62.0 , 63.4)			
1 Hodgkin Lymphoma	8,122	86.5 (85.5 , 87.4)	97.8 (96.3 , 98.7)	89.5 (88.4 , 90.4)	59.0 (54.8 , 62.9)			
1(a) Classical Hodgkin lymphoma	7,416	85.3 (84.3 , 86.3)	97.4 (95.7 , 98.5)	88.8 (87.7 , 89.8)	55.6 (51.3 , 59.7)			
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	1,310	84.1 (81.5 , 86.3)	99.3 (93.6 , 99.9)	87.3 (84.5 , 89.6)	61.2 (52.2 , 69.1)			
1(a)1.1 Lymphocyte-rich	252	89.6 (84.3 , 93.2)	95.8 (72.9 , 99.4)	94.7 (89.3 , 97.4)	58.3 (36.6 , 74.9)			
1(a)1.2 Mixed cellularity	985	84.3 (81.3 , 86.9)	100.0 (- , -)	87.1 (83.8 , 89.8)	62.8 (52.0 , 71.9)			
1(a)1.3 Lymphocyte-depleted	73	59.9 (46.2 , 71.2)	100.0 (- , -)	60.4 (43.9 , 73.3)	43.3 (20.8 , 64.0)			
1(a)2. Nodular sclerosis	3,799	90.4 (89.1 , 91.6)	98.3 (96.2 , 99.3)	92.2 (90.9 , 93.4)	60.3 (52.3 , 67.3)			
1(a)3. Classical Hodgkin lymphoma, NOS ^c	2,307	77.3 (75.0 , 79.3)	92.4 (85.1 , 96.1)	83.4 (81.1 , 85.5)	48.8 (41.9 , 55.3)			
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	706	97.6 (95.0 , 98.9)	100.0 (- , -)	96.0 (92.9 , 97.8)	98.1 (40.5 , 100.0)			
2 Non-Hodgkin lymphoma	95,555	70.8 (70.4 , 71.2)	88.9 (87.8 , 89.9)	76.3 (75.8 , 76.8)	63.3 (62.6 , 64.0)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	210	76.2 (67.6 , 82.7)	100.0 (- , -)	80.9 (71.7 , 87.3)	63.8 (44.0 , 78.3)			
4 Lymphoid neoplasm, NOS ^c	1,832	50.0 (47.0 , 52.8)	82.2 (71.1 , 89.3)	59.7 (55.6 , 63.5)	39.5 (35.4 , 43.5)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^c NOS = Not otherwise specified.

- Statistic not displayed due to less than 25 cases.